Ginseng in Treatment of Fatigue in Multiple Sclerosis
Palabras clave
Abstracto
Descripción
Multiple Sclerosis (MS) is one of the most common non-traumatic causes of disability in the world. It is a chronic inflammatory and demyelinating disorder of the Central Nervous System (CNS) which affects individuals in the productive ages and causes a large burden for years to come. Fatigue is a common complaint and one of the least understood symptoms of MS
fechas
| Verificado por última vez: | 09/30/2012 |
| Primero enviado: | 10/18/2012 |
| Inscripción estimada enviada: | 10/21/2012 |
| Publicado por primera vez: | 10/22/2012 |
| Última actualización enviada: | 10/21/2012 |
| Última actualización publicada: | 10/22/2012 |
| Fecha de inicio real del estudio: | 11/30/2010 |
| Fecha estimada de finalización primaria: | 03/31/2011 |
| Fecha estimada de finalización del estudio: | 03/31/2011 |
Condición o enfermedad
Intervención / tratamiento
Drug: Ginseng
Drug: Placebo
Fase
Grupos de brazos
| Brazo | Intervención / tratamiento |
|---|---|
| Active Comparator: Ginseng Ginseng, tablet, 250 mg, twice, 3 months | Drug: Ginseng it is kind of drug |
| Placebo Comparator: Placebo Placebo, tablet | Drug: Placebo it is placebo |
Criterio de elegibilidad
| Edades elegibles para estudiar | 18 Years A 18 Years |
| Sexos elegibles para estudiar | All |
| Acepta voluntarios saludables | si |
| Criterios | Inclusion Criteria: - definite diagnosis of relapsing-remitting MS (RRMS) by the MacDonald criteria with a baseline of Expanded Disability Status Score (EDSS)of less than 5.0 Exclusion Criteria: - prior use of ginseng or any other tonic agents, glucocorticoids, warfarin, digoxin, aspirin, furosemide, caffeine, ephedra and anti-platelet agents within one month prior to enrollment; - Pregnancy or lactation; - history of renal failure; and, - lack of appropriate adherence to the study protocol. |
Salir
Medidas de resultado primarias
1. Fatigue [at 3 months after treatment]
Medidas de resultado secundarias
1. Quality Of Life [at 3 months after treatment]
